Skip to main content
SpringerLink
Log in

Roles of the Insulin-Like Growth Factor System and Nutrition in Cancer

  • Chapter
Book cover IGF and Nutrition in Health and Disease

Part of the book series: Nutrition and Health ((NH))

  • 189 Accesses

Abstract

  • Nutrition plays a major role in regulating the IGF axis.

  • IGF-I is implicated in mediating the effects of nutrition on somatic growth.

  • Nutrition is associated with the incidence of a range of cancers.

  • IGF system is implicated in cancer.

  • IGF-I may mediate the effects of nutrition on neoplastic growth.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Folkman J, Hahnfeldt P, Hlatky L. Cancer: looking outside the genome.Nat rev Mol Cell Biol 2000; 1: 76–79

    Article  PubMed  CAS  Google Scholar 

  2. Li FP. Identification and management of inherited cancer susceptibility. Environ Health Perspect 1995; 103 (Suppl 8): 297–300.

    Article  PubMed  Google Scholar 

  3. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78–85.

    Article  PubMed  CAS  Google Scholar 

  4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3–34.

    PubMed  CAS  Google Scholar 

  5. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472–1489.

    Article  PubMed  CAS  Google Scholar 

  6. Tricoli JV, Rall LB, Karakousis CP, et al. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986; 46: 6169–6173.

    PubMed  CAS  Google Scholar 

  7. Cariani E, Lasserre C, Seurin D, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988; 48: 6844–6849.

    PubMed  CAS  Google Scholar 

  8. Rogler CE, Yang D, Rossetti L, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269: 13779–13784.

    PubMed  CAS  Google Scholar 

  9. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995; 72: 1189–1193.

    Article  PubMed  CAS  Google Scholar 

  10. Hirano H, Lopes MB, Laws ER, Jr., et al. Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro-onco11999; 1: 109–119.

    Google Scholar 

  11. Sohda T, Oka Y, Iwata K, et al. Co-localisation of insulin-like growth factor II and the proliferation marker MIB1 in hepatocellular carcinoma cells. J Clin Pathol 1997; 50: 135–137.

    Article  PubMed  CAS  Google Scholar 

  12. Kawamoto K, Onodera H, Kondo S, et al. Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival. Oncology 1998; 55: 242–248.

    Article  PubMed  CAS  Google Scholar 

  13. Guerra FK, Eijan AM, Puricelli L, et al. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 1996; 65: 812–820.

    Article  PubMed  CAS  Google Scholar 

  14. LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ. The role of the insulin-like growth factor-I receptor in cancer. Ann N Y Acad Sci 1995; 766: 402–408.

    Article  PubMed  CAS  Google Scholar 

  15. Braulke T. Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 1999; 31: 242–246.

    Article  PubMed  CAS  Google Scholar 

  16. Papa V, Gliozzo B, Clark GM, et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993; 53: 3736–3740.

    PubMed  CAS  Google Scholar 

  17. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996; 56: 1761–1765.

    PubMed  CAS  Google Scholar 

  18. Jammes H, Peyrat JP, Ban E, et al. Insulin-like growth factor 1 receptors in human breast tumour: localisation and quantification by histo-autoradiographic analysis. Br J Cancer 1.992; 66: 248–253.

    Google Scholar 

  19. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133–137.

    Article  PubMed  CAS  Google Scholar 

  20. Peruzzi F, Prisco M, Dews M, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19: 7203–7215.

    PubMed  CAS  Google Scholar 

  21. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999; 59: 3588–3591.

    PubMed  CAS  Google Scholar 

  22. Long L, Rubin R, Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998; 238: 116–121.

    Article  PubMed  CAS  Google Scholar 

  23. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999; 59: 2203–2209.

    PubMed  CAS  Google Scholar 

  24. Sciacca L, Costantino A, Pandini G, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999; 18: 2471–2479.

    Article  PubMed  CAS  Google Scholar 

  25. Pandini G, Vigneri R, Costantino A, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5: 1935–1944.

    PubMed  CAS  Google Scholar 

  26. Oates AJ, Schumaker LM, Jenkins SB, et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998; 47: 269–281.

    Article  PubMed  CAS  Google Scholar 

  27. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11: 447–449.

    Article  PubMed  Google Scholar 

  28. Byrd JC, Devi GR, de Souza AT, Jirtle RL, MacDonald RG. Disruption of ligand binding to the insulin-like growth factor IUmannose 6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 1999; 274: 24408–24416.

    Article  PubMed  CAS  Google Scholar 

  29. O’Gorman DB, Costello M, Weiss J, Firth SM, Scott CD. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res 1999; 59: 5692–5694.

    PubMed  Google Scholar 

  30. Souza RF, Wang S, Thakar M, et al. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 1999; 18: 4063–4068.

    Article  PubMed  CAS  Google Scholar 

  31. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 270: 13589–13592.

    Article  PubMed  CAS  Google Scholar 

  32. Shemer J, Yaron A, Werner H, et al. Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid. J Clin Endocrinol Metab 1993; 77: 1246–1250.

    Article  PubMed  CAS  Google Scholar 

  33. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998; 20: 157–162.

    Article  PubMed  CAS  Google Scholar 

  34. Karas M, Kleinman D, Danilenko M, et al. Components of the IGF system mediate the opposing effects of tamoxifen on endometrial and breast cancer cell growth. Prog Growth Factor Res 1995; 6: 513–520.

    Article  PubMed  CAS  Google Scholar 

  35. Nishimura A, Fujimoto M, Oguchi S, Fusunyan RD, MacDermott RP, Sanderson IR. Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells. Am J Physiol 1998; 275: E55 - E63.

    PubMed  CAS  Google Scholar 

  36. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993; 268: 14964–14971.

    PubMed  CAS  Google Scholar 

  37. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JM. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer 2000; 88: 336–341.

    Article  PubMed  CAS  Google Scholar 

  38. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM. Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J Cell Biochem 1999; 75: 652–664.

    Article  PubMed  CAS  Google Scholar 

  39. Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 1997; 272: 25602–607.

    Article  PubMed  CAS  Google Scholar 

  40. Williams AC, Collard TJ, Perks CM, et al. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 2000; 60: 22–27.

    PubMed  CAS  Google Scholar 

  41. Damon SE, Haugk KL, Birnbaum RS, Quinn LS. Retrovirally mediated overexpression of insulin-like growth factor binding protein 4: evidence that insulin-like growth factor is required for skeletal muscle differentiation. J Cell Physiol 1998; 175: 109–120.

    Article  PubMed  CAS  Google Scholar 

  42. Zumkeller W, Schwander J, Mitchell CD, Morrell DJ, Schofield PN, Preece MA. Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms’ tumour. Eur J Cancer 1993; 14: 1973–1977.

    Article  Google Scholar 

  43. Rutanen EM, Wahlstrom T, Koistinen R, Sipponen P, Jalanko H, Seppala M. Placental protein 12 (PP12) in primary liver cancer and cirrhosis. Tumour Biol 1984; 5: 95–102.

    PubMed  CAS  Google Scholar 

  44. Renehan AG, Jones J, Potten CS, Shalet SM, O’Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000; 83: 1344–1350.

    Article  PubMed  CAS  Google Scholar 

  45. Rocha RL, Hilsenbeck SG, Jackson JG, et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997; 3: 103–109.

    PubMed  CAS  Google Scholar 

  46. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues:

    Google Scholar 

  47. detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 1996; 88: 601–606.

    Article  Google Scholar 

  48. Maile LA, Holly JM. Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Growth Horm IGF Res 1999; 9: 85–95.

    Article  PubMed  CAS  Google Scholar 

  49. Koistinen H, Paju A, Koistinen R, et al. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP3. Prostate 2002; 50: 112–118.

    Article  PubMed  CAS  Google Scholar 

  50. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–566.

    Article  PubMed  CAS  Google Scholar 

  51. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393–1396.

    Article  PubMed  CAS  Google Scholar 

  52. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620–625.

    Article  PubMed  CAS  Google Scholar 

  53. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prey 2000; 9: 345–349.

    CAS  Google Scholar 

  54. Petridou E, Dessypris N, Spanos E, et al. Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. Int J Cancer 1999; 80: 49496.

    Article  Google Scholar 

  55. Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. Growth Horm IGF Res 2000; 10 (Suppl A): S26 - S27.

    Article  PubMed  Google Scholar 

  56. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001; 85: 991–996.

    Article  PubMed  CAS  Google Scholar 

  57. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 2001; 85: 428–430.

    Article  PubMed  CAS  Google Scholar 

  58. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96: 7324–7329.

    Article  PubMed  CAS  Google Scholar 

  59. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002; 62: 1030–1035.

    PubMed  CAS  Google Scholar 

  60. Gunnell D. Commentary: Early insights into height, leg length, proportionate growth and health. Int J Epidemiol 2001; 30: 221–222.

    Article  PubMed  CAS  Google Scholar 

  61. Maison P, Balkau B, Simon D, Chanson P, Rosselin G, Eschwege E. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. Bmj 1998; 316: 1132–1133.

    Article  PubMed  CAS  Google Scholar 

  62. Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 1997; 47: 17–22.

    Article  CAS  Google Scholar 

  63. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411: 390–395.

    Article  PubMed  CAS  Google Scholar 

  64. Riboli E, Norat T. Cancer prevention and diet: opportunities in Europe. Public Health Nutr 2001; 4: 475–484.

    Article  PubMed  CAS  Google Scholar 

  65. Greenwald P, Clifford CK, Milner JA. Diet and cancer prevention. Eur J Cancer 2001; 37: 948–965.

    Article  PubMed  CAS  Google Scholar 

  66. Frankel S, Gunnell DJ, Peters TJ, Maynard M, Davey Smith G. Childhood energy intake and adult mortality from cancer: the Boyd Orr Cohort Study. BMJ 1998; 316: 499–504.

    Article  PubMed  CAS  Google Scholar 

  67. Gunnell DJ, Davey Smith G, Frankel S, et al. Childhood leg length and adult mortality: follow up of the Carnegie (Boyd Orr) Survey of Diet and Health in Pre-war Britain. J Epidemiol Community Health 1998; 52: 142–152.

    Article  PubMed  CAS  Google Scholar 

  68. Hursting SD, Perkins SN, Phang JM. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci USA 1994; 91: 7036–7040.

    Article  PubMed  CAS  Google Scholar 

  69. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999; 91: 512–523.

    Article  PubMed  CAS  Google Scholar 

  70. Spady TJ, Lemus-Wilson AM, Pennington KL, et al. Dietary energy restriction abolishes development of prolactin-producing pituitary tumors in Fischer 344 rats treated with 17beta-estradiol. Mol Carcinog 1998; 23: 86–95.

    Article  PubMed  CAS  Google Scholar 

  71. Lagopoulos L, Sunahara GI, Wurzner H, Dombrowsky I, Stalder R. The effects of alternating dietary restriction and ad libitum feeding of mice on the development of diethylnitrosamine-induced liver tumours and its correlation to insulinaemia. Carcinogenesis 1991; 12: 311–315.

    Article  PubMed  CAS  Google Scholar 

  72. Hursting SD, Switzer BR, French JE, Kari FW. The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats. Cancer Res 1993; 53: 2750–2757.

    PubMed  CAS  Google Scholar 

  73. Dunn SE, Kari FW, French J, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 4667–72.

    PubMed  CAS  Google Scholar 

  74. Ma J, Giovannucci E, Pollak M, et al. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst 2001; 93: 1330–1336.

    Article  PubMed  CAS  Google Scholar 

  75. Chlebowski RT. Breast cancer risk reduction: strategies for women at increased risk. Annu Rev Med 2002; 53: 519–540.

    Article  PubMed  CAS  Google Scholar 

  76. Helle SI, Holly JM, Tally M, Hall K, Vander Stappen J, Lonning PE. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996; 69: 335–339.

    Article  PubMed  CAS  Google Scholar 

  77. Torrisi R, Baglietto L, Johansson H, et al. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 2001; 85: 1838–1841.

    Article  PubMed  CAS  Google Scholar 

  78. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989; 9: 889–891.

    PubMed  CAS  Google Scholar 

  79. Mucci LA, Tamimi R, Lagiou P, et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001; 87: 814–820.

    Article  PubMed  CAS  Google Scholar 

  80. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographie density. Cancer Res 2000; 60: 3744–3748.

    PubMed  CAS  Google Scholar 

  81. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393–1396.

    Article  PubMed  CAS  Google Scholar 

  82. Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83: 775–779.

    Article  PubMed  CAS  Google Scholar 

  83. Cats A, Dullaart RP, Kleibeuker JH, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996; 56: 523–526.

    PubMed  CAS  Google Scholar 

  84. Holly JM, Gunnell DJ, Davey Smith G. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol 1999; 162: 321–330.

    Google Scholar 

Download references

Authors
  1. Claire M. Perks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey M. P. Holly
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Food and Nutrition Program, School of Family and Consumer, Bowling Green State University, Bowling Green, OH, USA

    M. Sue Houston PhD, RD

  2. Division of Surgery, Department of Hospital Medicine, Bristol Royal Infirmary, Bristol, UK

    Jeffrey M. P. Holly PhD

  3. JDRF Center for the Study of Complications in Diabetes, Department of Neurology, University of Michigan, Ann Arbor, MI, USA

    Eva L. Feldman MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Perks, C.M., Holly, J.M.P. (2004). Roles of the Insulin-Like Growth Factor System and Nutrition in Cancer. In: Houston, M.S., Holly, J.M.P., Feldman, E.L. (eds) IGF and Nutrition in Health and Disease. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-795-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-795-6_18

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-412-8

  • Online ISBN: 978-1-59259-795-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation